Oncomedics at the IMODI consortium
Oncomedics is very pleased to announce its participation in the IMODI (Innovative Models Initiative) consortium funded under the French Government’s “Investing for the Future” program. Its goal is to enable the development of new drugs and personalized medicine approaches in cancer by creating new predictive cancer models. Our OncoTRIP platform and our Oncogramme approach will be integrated in this project where the largest pharmaceutical companies (Sanofi, Servier, Pierre Fabre and Ipsen) and the most prestigious academic centers (CNRS, INSERM, AP-HP, CLB Lyon, CHU Toulouse, SLC Lyon, CGFL Dijon, Université de Strasbourg, …) are fully implicated.
For additional information, please follow the link www.imodi-cancer.org